Pravachol Faces Erosion, But Favorable Rebates Yield Q2 Sales Gain
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb’s cholesterol-lowering agent benefits from lower Medicaid and managed care rebate rates, helping drive 8% sales gain in U.S.
You may also be interested in...
Bristol Settles DoJ "Channel Stuffing" Investigation For $300 Mil.
The company will take a $249 mil. charge in the second quarter, in addition to a first quarter charge of $51 mil. The monies will be added to a shareholder fund created under a separate, earlier settlement with SEC. CEO Dolan loses his chairman's title under the pact, and Bristol agrees to cooperate with investigations of former executives.
Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning
Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.
MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology
Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.